Companies Amylyx Pharmaceuticals
Amylyx Pharmaceuticals (AMLX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Amylyx Pharmaceuticals’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers45th pct.Of 18 peer CEOs
CEO pay, last three years
- $7,418,169FY2023
- $6,496,255FY2024
- $2,719,807FY2025
CEO total pay was $2,719,807 in fiscal 2025, down from $6,496,255 in fiscal 2024.
FY2025: salary $686,200 · bonus $0 · stock awards $650,226 · option awards $817,783
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Amylyx Pharmaceuticals in fiscal 2025?
As disclosed, Justin Klee (Co-Chief Executive Officer and Director) was the highest-paid executive at Amylyx Pharmaceuticals in fiscal 2025, with total compensation of $2,719,807.
How does Amylyx Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Joshua Cohen's total compensation ranked at the 45th percentile of Amylyx Pharmaceuticals's disclosed peer group.
What is Amylyx Pharmaceuticals's CEO-to-median employee pay ratio?
As disclosed, Amylyx Pharmaceuticals's CEO-to-median employee pay ratio was 9:1.
How did shareholders vote on Amylyx Pharmaceuticals's executive compensation?
As disclosed, 85.18% of shareholders supported Amylyx Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Amylyx Pharmaceuticals spend in total on board compensation for fiscal 2025?
As disclosed, Amylyx Pharmaceuticals reported total board compensation of $382,500 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Justin Klee | $686,200 | $0 | $650,226 | $817,783 | $548,098 | $0 | $17,500 | $2,719,807 |
| Co-Chief Executive Officer and Director | ||||||||
| Joshua Cohen | 686,200 | 0 | 650,226 | 817,783 | 548,098 | 0 | 17,500 | 2,719,807 |
| Co-Chief Executive Officer and Director | ||||||||
| Camille Bedrosian | 575,000 | 0 | 246,996 | 312,872 | 275,569 | 0 | 157,237 | 1,567,674 |
| Chief Medical Officer | ||||||||
| James Frates | 540,600 | 0 | 246,996 | 311,148 | 259,083 | 0 | 17,500 | 1,375,327 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Justin Klee | $2,719,807 | $6,496,255 | $7,418,169 | ↓ −3,776,448 |
| Joshua Cohen | 2,719,807 | 6,496,255 | 7,418,169 | ↓ −3,776,448 |
| Camille Bedrosian | 1,567,674 | — | 2,372,859 | — |
| James Frates | 1,375,327 | 2,540,353 | 3,510,377 | ↓ −1,165,026 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The key objectives of our executive compensation program are to attract, motivate, retain, and reward leaders who create an inclusive and diverse environment and have the skills and experience necessary to successfully execute on our strategic plan to maximize stockholder value.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Camille Bedrosian | OPTION | — | — | — | — | — | $312,872 |
| Justin Klee | PRSU | — | — | — | — | — | 650,226 |
| James Frates | OPTION | — | — | — | — | — | 311,148 |
| Justin Klee | OPTION | — | — | — | — | — | 817,783 |
| Joshua Cohen | PRSU | — | — | — | — | — | 650,226 |
| Joshua Cohen | OPTION | — | — | — | — | — | 817,783 |
| James Frates | PRSU | — | — | — | — | — | 246,996 |
| Camille Bedrosian | PRSU | — | — | — | — | — | 246,996 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Camille Bedrosian | $0 | $0 | $312,872 | 0.0% |
| Justin Klee | 0 | 0 | 817,783 | 0.0% |
| James Frates | 0 | 0 | 311,148 | 0.0% |
| Joshua Cohen | 0 | 0 | 817,783 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| James Frates | Option | 1,042 | 19.63 | — |
| James Frates | Option | 2,969 | 19 | — |
| Joshua Cohen | Option | 7,032 | 19 | — |
| Justin Klee | Option | 7,032 | 19 | — |
| James Frates | RSU | 7,917 | — | 95,637 |
| James Frates | RSU | 10,834 | — | 130,875 |
| Joshua Cohen | RSU | 18,750 | — | 226,500 |
| Justin Klee | RSU | 18,750 | — | 226,500 |
| Joshua Cohen | RSU | 25,000 | — | 302,000 |
| Justin Klee | RSU | 25,000 | — | 302,000 |
| Camille Bedrosian | RSU | 29,167 | — | 352,337 |
| James Frates | RSU | 30,000 | — | 362,400 |
| James Frates | Option | 30,469 | 32.08 | — |
| James Frates | Option | 32,500 | 17.56 | — |
| James Frates | RSU | 68,420 | — | 826,514 |
| James Frates | PSU | 68,420 | — | 826,514 |
| Camille Bedrosian | RSU | 68,420 | — | 826,514 |
| Camille Bedrosian | PSU | 68,420 | — | 826,514 |
| James Frates | Option | 70,000 | 2.01 | — |
| Camille Bedrosian | Option | 70,000 | 2.01 | — |
| Joshua Cohen | Option | 70,313 | 32.08 | — |
| Justin Klee | Option | 70,313 | 32.08 | — |
| Camille Bedrosian | Option | 81,250 | 12.93 | — |
| Joshua Cohen | RSU | 95,001 | — | 1,147,612 |
| Justin Klee | RSU | 95,001 | — | 1,147,612 |
| James Frates | Option | 102,630 | 3.61 | — |
| Camille Bedrosian | Option | 102,630 | 3.61 | — |
| Joshua Cohen | Option | 102,917 | 17.56 | — |
| Justin Klee | Option | 102,917 | 17.56 | — |
| Joshua Cohen | RSU | 180,118 | — | 2,175,825 |
| Joshua Cohen | PSU | 180,118 | — | 2,175,825 |
| Justin Klee | RSU | 180,118 | — | 2,175,825 |
| Justin Klee | PSU | 180,118 | — | 2,175,825 |
| Joshua Cohen | Option | 221,667 | 2.01 | — |
| Justin Klee | Option | 221,667 | 2.01 | — |
| Joshua Cohen | Option | 270,177 | 3.61 | — |
| Justin Klee | Option | 270,177 | 3.61 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| George Mclean Milne Jr., Ph.DIndependent · Board Chair · Audit · Compensation · Nominating/Governance (Chair) · Science and Technology | $117,500 | $0 | $101,078 | $0 | $0 | $218,578 |
| Daphne QuimiIndependent · Audit (Chair) · Compensation | 72,500 | 0 | 101,078 | 0 | 0 | 173,578 |
| Paul FonteyneIndependent · Compensation (Chair) · Science and Technology | 67,500 | 0 | 101,078 | 0 | 0 | 168,578 |
| Bernhardt Zeiher, M.DIndependent · Nominating/Governance · Science and Technology (Chair) | 65,000 | 0 | 101,078 | 0 | 0 | 166,078 |
| Karen FirestoneIndependent · Audit · Nominating/Governance | 60,000 | 0 | 101,078 | 0 | 0 | 161,078 |
| Justin KleeEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Joshua CohenEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $285,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $382,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $382,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Amylyx Pharmaceuticals as a peer
Companies that benchmark against AMLX
6 companies name AMLX as a compensation peer
The list of companies that name AMLX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
CTMX CytomX Therapeutics, Inc.ADVM Adverum Biotechnologies, Inc.BCAB BioAtla, Inc.BMEA Biomea Fusion, Inc.CMRX Chimerix, Inc.IMUX Immunic, Inc.INZY Inozyme Pharma, Inc.PEPG PepGen Inc.PYXS Pyxis Oncology, Inc.RAPT RAPT Therapeutics, Inc.VIGL Vigil Neuroscience, Inc.GOSS Gossamer Bio, Inc.ACRS Aclaris Therapeutics, Inc.ATYR aTyr Pharma, IncAURA Aura Biosciences, Inc. Syros Pharmaceuticals, Inc.VSTM Verastem, Inc.XBIT XBiotech Inc.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Rapt Therapeutics, Inc. | 2024 | Brian Wong | $630,000 | $0 | $5,927,297 | $416,000 | $6,979,539 |
| 2 | CytomX Therapeutics, Inc. | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 3 | Adverum Biotechnologies, Inc. | 2024 | Laurent Fischer | 691,795 | 171,363 | 2,839,252 | 415,080 | 4,131,290 |
| 4 | Aura Biosciences, Inc. | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 5 | aTyr Pharma, Inc | 2025 | Sanjay Shukla | 638,977 | 0 | 2,595,200 | 210,862 | 3,456,253 |
| 6 | Aclaris Therapeutics, Inc. | 2025 | Neal Walker | 615,000 | 828,426 | 1,581,615 | 350,550 | 3,375,591 |
| 7 | PepGen Inc. | 2025 | James McArthur | 619,000 | 170,620 | 2,088,547 | 0 | 3,316,783 |
| 8 | Amylyx Pharmaceuticals | 2025 | Joshua Cohen | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 9 | Vigil Neuroscience, Inc. | 2024 | Ivana Magovčević-Liebisch | 620,000 | 0 | 1,692,871 | 306,900 | 2,633,571 |
| 10 | Inozyme Pharma, Inc. | 2024 | Douglas Treco | 541,667 | 0 | 1,933,375 | 0 | 2,485,392 |
| 11 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 12 | Gossamer Bio, Inc. | 2025 | Faheem Hasnain | 649,649 | 0 | 1,392,006 | 254,800 | 2,300,455 |
| 13 | Chimerix, Inc. | 2023 | Mike Andriole | 528,473 | 93,135 | 399,282 | 280,500 | 1,312,421 |
| 14 | XBiotech Inc. | 2025 | Sushma Shivaswamy | 468,557 | 0 | 0 | 0 | 570,992 |
| — | BioAtla, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Biomea Fusion, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Pyxis Oncology, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Amylyx Pharmaceuticals | 106.5% | not disclosed | No | Pearl Meyer |
| Aclaris Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Adverum Biotechnologies, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| aTyr Pharma, Inc | 60% (Committee lowered payout from 75% achievement to 60% given EFZO-FIT study results)% | Option 100 | not disclosed | Radford (part of the Rewards Solutions practice at Aon plc) |
| Aura Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance |
| BioAtla, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Biomea Fusion, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Chimerix, Inc. | 85% | Option 86 · RSU 14 | not disclosed | Aon |
| CytomX Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Gossamer Bio, Inc. | 65% | not disclosed | No | Alpine Rewards |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Inozyme Pharma, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| PepGen Inc. | not disclosed | not disclosed | not disclosed | Pay Governance, LLC |
| Pyxis Oncology, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Rapt Therapeutics, Inc. | 120% | Option 100 | not disclosed | Aon plc/Radford |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Vigil Neuroscience, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| XBiotech Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-04 | 77,534,824 | 13,490,653 | 21,125 | 85.18% | Passed |
| 2025 | 2025-06-05 | 33,080,252 | 24,050,998 | 2,024,272 | 57.9% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-04 | 85.18%a |
| 2025 | 2025-06-05 | 57.9%b |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will have no effect on the outcome of the vote on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 9 : 1 |
|---|---|
| CEO total compensation | $2,719,807 |
| Median employee compensation | $298,360 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Karen Firestone | Director | 2026-05-21 | A | 3,800 | $14 | $51,338 | Common | Form 4 ↗ |
| Bernhardt G. Zeiher | Director | 2026-06-04 | A | 24,372 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Fonteyne | Director | 2026-06-04 | A | 24,372 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George M. Milne Jr | Director | 2026-06-04 | A | 24,372 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daphne Quimi | Director | 2026-06-04 | A | 24,372 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Firestone | Director | 2026-06-04 | A | 24,372 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gina Mazzariello | Chief Legal Officer | 2026-07-09 | D | 15,000 | 18 | 274,746 | Common | Form 4 ↗ |
| Gina Mazzariello | Chief Legal Officer | 2026-07-10 | D | 15,000 | 18 | 264,122 | Common | Form 4 ↗ |
| Camille Bedrosian | Chief Medical Officer | 2026-08-18 | A | 22,807 | 0 | 0 | Common | Form 4 ↗ |
| Gina Mazzariello | Chief Legal Officer | 2026-08-18 | A | 21,284 | 0 | 0 | Common | Form 4 ↗ |
| Joshua Cohen | Director | 2026-08-18 | A | 60,039 | 0 | 0 | Common | Form 4 ↗ |
| Justin Klee | Director | 2026-08-18 | A | 60,039 | 0 | 0 | Common | Form 4 ↗ |
| James Frates | Chief Financial Officer | 2026-08-18 | A | 22,807 | 0 | 0 | Common | Form 4 ↗ |
| Karen Firestone | Director | 2026-08-31 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Firestone | Director | 2026-08-31 | D | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Firestone | Director | 2026-08-31 | A | 25,000 | 5 | 126,250 | Common | Form 4 ↗ |
| Karen Firestone | Director | 2026-08-31 | A | 25,000 | 2 | 44,000 | Common | Form 4 ↗ |
| Gina Mazzariello | Chief Legal Officer | 2026-09-10 | D | 11 | 33 | 367 | Common | Form 4 ↗ |
| Camille Bedrosian | Chief Medical Officer | 2026-09-10 | D | 2,081 | 33 | 68,864 | Common | Form 4 ↗ |
| Camille Bedrosian | Chief Medical Officer | 2026-09-10 | D | 7,947 | 32 | 256,004 | Common | Form 4 ↗ |
| Justin Klee | Director | 2026-09-10 | D | 29,025 | 32 | 932,553 | Common | Form 4 ↗ |
| Gina Mazzariello | Chief Legal Officer | 2026-09-10 | D | 9,525 | 32 | 309,140 | Common | Form 4 ↗ |
| Joshua Cohen | Director | 2026-09-10 | D | 919 | 33 | 30,464 | Common | Form 4 ↗ |
| Joshua Cohen | Director | 2026-09-10 | D | 29,545 | 32 | 950,040 | Common | Form 4 ↗ |
| James Frates | Chief Financial Officer | 2026-09-10 | D | 1,042 | 33 | 34,626 | Common | Form 4 ↗ |
| James Frates | Chief Financial Officer | 2026-09-10 | D | 9,768 | 32 | 315,195 | Common | Form 4 ↗ |
| Justin Klee | Director | 2026-09-10 | D | 1,439 | 33 | 47,710 | Common | Form 4 ↗ |
| George M. Milne Jr | Director | 2026-10-05 | D | 30,000 | 28 | 830,904 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (67 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Justin Klee. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table”. As printed: 2,719,807. View filing ↗
- Section 01, Joshua Cohen. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table” · page 28. As printed: 2,719,807. View filing ↗
- Section 01, Camille Bedrosian. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table”. As printed: 1,567,674. View filing ↗
- Section 01, James Frates. DEF 14A, filed 2026-04-23. Section “2025 Summary Compensation Table”. As printed: 1,375,327. View filing ↗
- Section 03, Camille Bedrosian OPTION. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Justin Klee PRSU. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, James Frates OPTION. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Justin Klee OPTION. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Joshua Cohen PRSU. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Joshua Cohen OPTION. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, James Frates PRSU. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Camille Bedrosian PRSU. DEF 14A, filed 2026-04-23. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-23. Section “CEO Pay Ratio”. As printed: 9 : 1. View filing ↗
- Section 08, George Mclean Milne Jr., Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 218,578. View filing ↗
- Section 08, Daphne Quimi. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 173,578. View filing ↗
- Section 08, Paul Fonteyne. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 168,578. View filing ↗
- Section 08, Bernhardt Zeiher, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 166,078. View filing ↗
- Section 08, Karen Firestone. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 161,078. View filing ↗
- Section 08, Justin Klee. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Joshua Cohen. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Karen Firestone 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bernhardt G. Zeiher 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Fonteyne 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George M. Milne Jr 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daphne Quimi 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Firestone 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Mazzariello 2026-07-09. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Mazzariello 2026-07-10. Form 4, filed 2026-07-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Camille Bedrosian 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Mazzariello 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Cohen 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Klee 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Frates 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Firestone 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Firestone 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Firestone 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Firestone 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Mazzariello 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Camille Bedrosian 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Camille Bedrosian 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Klee 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gina Mazzariello 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Cohen 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Cohen 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Frates 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Frates 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Justin Klee 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George M. Milne Jr 2026-10-05. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-04. Item 5.07 · say-on-pay result. As reported: 85.18% (votes for as printed: 77,534,824). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-05. Item 5.07 · say-on-pay result. As reported: 57.9% (votes for as printed: 33,080,252). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 382,500 + equity 0 + all other 0 = 382,500, summed across the director compensation table rows.
- Rapt Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics, Inc.'s own proxy. As printed: 6,979,539. View filing ↗
- CytomX Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in CytomX Therapeutics, Inc.'s own proxy. As printed: 4,738,495. View filing ↗
- Adverum Biotechnologies, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Adverum Biotechnologies, Inc.'s own proxy. As printed: 4,131,290. View filing ↗
- Aura Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences, Inc.'s own proxy. As printed: 3,956,167. View filing ↗
- aTyr Pharma, Inc, Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in aTyr Pharma, Inc's own proxy. As printed: 3,456,253. View filing ↗
- Aclaris Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Aclaris Therapeutics, Inc.'s own proxy. As printed: 3,375,591. View filing ↗
- PepGen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in PepGen Inc.'s own proxy. As printed: 3,316,783. View filing ↗
- Amylyx Pharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Amylyx Pharmaceuticals's own proxy. As printed: 2,719,807. View filing ↗
- Vigil Neuroscience, Inc., Section 10b CEO total. DEF 14A, filed 2025-03-31. CEO total compensation as printed in Vigil Neuroscience, Inc.'s own proxy. As printed: 2,633,571. View filing ↗
- Inozyme Pharma, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Inozyme Pharma, Inc.'s own proxy. As printed: 2,485,392. View filing ↗
- Verastem, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. View filing ↗
- Gossamer Bio, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Gossamer Bio, Inc.'s own proxy. As printed: 2,300,455. View filing ↗
- Chimerix, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix, Inc.'s own proxy. As printed: 1,312,421. View filing ↗
- XBiotech Inc., Section 10b CEO total. DEF 14A, filed 2026-10-02. CEO total compensation as printed in XBiotech Inc.'s own proxy. As printed: 570,992. View filing ↗